Understanding how lung cancer evolves resistance to treatments
Official title: Exploiting Ecology and Evolution to Prevent Therapy Resistance in EGFR-Driven Lung Cancer
Funded at Cleveland Clinic Lerner Com-Cwru · NIH-10883460 · Data updated 2026-11-12
This study looks at how lung cancer cells with EGFR mutations change and resist treatment, hoping to find new ways to help patients by understanding these changes better.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project start | December 1, 2024 |
| Project end | November 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $497,509 |
| NIH project number | 4R37CA244613-06 |
| Project ID | NIH-10883460 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with EGFR-mutated non-small cell lung cancer.
✕Less likely to help
Patients with lung cancer that does not involve EGFR mutations may not benefit from this research.
What this research studies
This research investigates the mechanisms behind therapy resistance in EGFR-driven lung cancer by examining the ecological and evolutionary processes within tumors. It employs a combination of mathematical modeling and experimental techniques to analyze how cancer cells interact and evolve in response to treatment. By focusing on the dynamics of these interactions, the research aims to identify new strategies for drug design that could prevent or delay resistance. Patients with EGFR mutations in non-small cell lung cancer may benefit from insights gained through this innovative approach.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that effectively prevent resistance in lung cancer therapies.
How similar studies have gone: While the focus on eco-evolutionary processes in cancer is relatively novel, similar approaches in understanding drug resistance have shown promise in other cancer types.
Where this research is happening
-
Cleveland Clinic Lerner Com-Cwru
Cleveland, United States Active
Researchers
- Principal investigator: Scott, Jacob Gardinier — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Scott, Jacob Gardinier
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.